Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

Guizhou Medical University

ClinicalTrials.gov lists Guizhou Medical University as lead sponsor of 11 trials. It has 6 approved assets.

CN Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

6 0 2012 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.

This page covers Guizhou Medical University: 11 lead-sponsored trials and 0 legal-entity registrations.

Get the Guizhou Medical University report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (22)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Lung Neoplasms 7
Carcinoma, Non-Small-Cell Lung 5
Head and Neck Neoplasms 3
Parasomnias 2
Parkinson Disease 2

Showing 5 of 22 disease areas.

Start your 14-day trial Email me all 22 disease areas as a PDF

Trials by start year as sponsor or collaborator (13)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2025 2
2023 2
2022 2
2021 3
2020 2
2019 1
2018 6
2017 1
2016 1

Showing 10 of 13 years.

Start your 14-day trial Email me all 13 years as a PDF

Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; 5 of 5 predicted trials reach the 36-month horizon. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Approved assets (6)

Shown in this order: max phase first.

Approved assets
Drug Trials
Reboxetine 1
Citalopram 1
VENLAFAXINE 1
Sertraline 1
CISPLATIN 3

Showing 5 of 6 approved assets.

Start your 14-day trial Email me all 6 approved assets as a PDF

Journals published in (7)

Shown in this order: most published in first.

Journals published in
Journal Publications
Anti-cancer drugs 1
BMJ open 1
Chest 1
JAMA 1
Journal of cancer research and clinical oncology 1

Showing 5 of 7 journals.

Start your 14-day trial Email me all 7 journals as a PDF

Organization relationships (33)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
First Affiliated Hospital of Dalian Medical University Co sponsors trial with 2
Qilu Hospital of Shandong University Co sponsors trial with 2
Huashan Hospital Co sponsors trial with 2
First Affiliated Hospital of Anhui Medical University Co sponsors trial with 2
Second Affiliated Hospital, Zhejiang University, School of Medicine Co sponsors trial with 2

Showing 5 of 33 relationships.

Start your 14-day trial Email me all 33 relationships as a PDF

Latest dated events (24)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-03-30 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-04-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-03-03 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2023-09-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2023-01-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 24 events.

Start your 14-day trial Email me all 24 events as a PDF

Biomarker capability evidence (36)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALK Trial sponsor Named in trial inclusion criteria
ALK Trial sponsor Named in trial inclusion criteria
ALK Trial sponsor Named in trial inclusion criteria
ALK Trial sponsor Named in trial inclusion criteria
DEGS1 Trial sponsor Named in trial inclusion criteria

Showing 5 of 36 evidence rows.

Start your 14-day trial Email me all 36 evidence rows as a PDF

Biomarkers this organization publishes on (116)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
CD4 3
CD8A 3
CTLA4 3
CASP3 2
CD274 2

Showing 5 of 116 biomarkers.

Start your 14-day trial Email me the first 50 biomarkers as a PDF

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.